Camrelizumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	82	43	33	276	—	—	Apr 6, 2016
Malignant Liver Neoplasm	Phase3	Phase 3	12	7	6	29	—	—	2016-10
Malignant Breast Neoplasm	Phase3	Phase 3	10	6	2	20	—	—	Apr 27, 2016
Malignant Esophageal Neoplasm	Phase3	Phase 3	6	2	5	27	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Low on-treatment bTMB1
Camrelizumab +

Clinical trials

Trials with this intervention (288)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 251–288 of 288 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04415385	The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma	unknown	Phase 2	48	Zhejiang Cancer HospitalOTHER	1	Jun 4, 2020	clinicaltrials
NCT04405154	A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer	unknown	Phase 2